|Poll|January 20, 2021

Discussions With Patients: Medical Marijuana

As our knowledge about herbal cannabis, the endocannabinoid system, and cannabinoid pharmacology expands, should psychiatrists discuss these issues with their patients?

Do you discuss medical marijuana/cannabis use for medical/psychiatric issues with your patients?

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Podcast: Early Intervention & Psychopharmacology in Bipolar Disorder With Robert M. Post, MD

ByJoseph F. Goldberg, MD,Robert M. Post, MD

June 5th 2026

Adjunctive Atypical Antipsychotics in Major Depressive Disorder: Comparing Efficacy and Tolerability

ByLeslie L. Citrome, MD, MPH

June 3rd 2026

Nonpharmacological Augmentation of Ketamine, Neuroplasticity, and Behavioral Therapy

ByWilliam Li, MD,Morgan Hardy, MD

June 2nd 2026

FDA Issues CRL for CTx-1301 for Treatment of ADHD

ByJessica Walters

June 2nd 2026

Balancing Efficacy and Risk in ADHD Pharmacotherapy

ByHelene Alphonso, DO

June 1st 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Discussions With Patients: Medical Marijuana

Related Content

Podcast: Early Intervention & Psychopharmacology in Bipolar Disorder With Robert M. Post, MD

Adjunctive Atypical Antipsychotics in Major Depressive Disorder: Comparing Efficacy and Tolerability

Nonpharmacological Augmentation of Ketamine, Neuroplasticity, and Behavioral Therapy

FDA Issues CRL for CTx-1301 for Treatment of ADHD

Balancing Efficacy and Risk in ADHD Pharmacotherapy

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Podcast: Early Intervention & Psychopharmacology in Bipolar Disorder With Robert M. Post, MD

New Positive Phase 2 Topline Data on Elunetirom for the Treatment of Bipolar Depression

Adjunctive Atypical Antipsychotics in Major Depressive Disorder: Comparing Efficacy and Tolerability

Suicide Risk Assessment in Patients Denying Suicidal Intent

AI-Driven Biomarker Discovery from Wearables in Neuropsychiatric Research